Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHRIL 500 vs AZASITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Mild to moderate pain,Fever
Treatment of bacterial conjunctivitis caused by susceptible organisms
500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 6-12 hours in hepatic impairment or overdose.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 (and CYP1A2, CYP3A4) produces the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Renal excretion of unchanged drug and glucuronide conjugate accounts for 90-95% of elimination; biliary/fecal elimination accounts for 5-10%.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
10-25% bound to plasma proteins (albumin).
~50-60% bound to plasma proteins (primarily albumin).
0.9-1.1 L/kg; indicates extensive distribution into body fluids including CSF.
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
Oral: 75-90% (first-pass metabolism reduces from near 100% absorption); IV: 100%; Rectal: 70-85%.
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
GFR 30-50 m L/min: 500 mg every 8 hours. GFR 10-29 m L/min: 500 mg every 12 hours. GFR <10 m L/min: 500 mg every 24 hours.
No dosage adjustment required for ophthalmic use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 500 mg every 8 hours. Child-Pugh Class C: 500 mg every 12 hours.
No dosage adjustment required for ophthalmic use.
Children <2 years: not recommended. Children 2-12 years: 10-15 mg/kg/dose every 6 hours, maximum 60 mg/kg/day. Adolescents >12 years: same as adult.
Safety and efficacy in pediatric patients have not been established; limited data available.
Initiate at 500 mg every 8 hours; increase interval if needed due to reduced renal function; consider maximum daily dose of 1500 mg.
No specific dosage adjustment recommended; use same dosing as for adults.
Risk of severe liver injury; do not exceed 4,000 mg per day in adults or 2,000 mg per day in patients with liver disease. Concomitant use with other acetaminophen-containing products may lead to overdose.
None
Hepatotoxicity, especially with doses >4 g/day or in patients with hepatic impairment; risk of acute generalized exanthematous pustulosis (AGEP); serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); avoid use with alcohol or other hepatotoxic drugs.
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Hypersensitivity to acetaminophen or any component; severe hepatic impairment; use of other acetaminophen-containing products concurrently.
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
No significant food interactions. Alcohol increases risk of hepatotoxicity and should be avoided.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
ETHIRIL 500 (ethyl alcohol 500 mg) is not a standard drug; assuming it refers to ethanol. Teratogenic: First trimester: Increased risk of fetal alcohol spectrum disorders (FASD) including craniofacial abnormalities, growth deficiency, and neurodevelopmental deficits with chronic heavy use. Second trimester: Risk of spontaneous abortion and intrauterine growth restriction (IUGR). Third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. No safe threshold established.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
Ethanol is excreted into breast milk. Milk-to-plasma ratio approximately 1.0. Peak milk levels occur 30-60 minutes after ingestion. Chronic heavy use may impair infant motor development and cause sedation. Avoid breastfeeding within 2 hours of alcohol consumption; excessive use contraindicated.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
No therapeutic dosing; ethanol is not indicated in pregnancy. If used inadvertently, pharmacokinetic changes: increased volume of distribution may lower peak alcohol concentration, but no dose adjustment recommendation. Avoidance is critical.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
ETHRIL 500 (acetaminophen 500 mg) is hepatotoxic in overdose; maximum daily dose is 4 g in adults, but reduce to 2 g in patients with hepatic impairment, alcoholism, or malnutrition. Administer N-acetylcysteine for overdose within 8 hours for best efficacy.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Do not exceed 4 g (eight 500 mg tablets) per day.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,Seek immediate medical attention if overdose is suspected.,Take with or without food as needed.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHRIL 500 vs AZASITE, answered by our medical review team.
ETHRIL 500 is a Macrolide Antibiotic that works by Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.. AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHRIL 500 and AZASITE depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHRIL 500 is: 500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.. The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHRIL 500 and AZASITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHRIL 500 is classified as Category C. ETHIRIL 500 (ethyl alcohol 500 mg) is not a standard drug; assuming it refers to ethanol. Teratogenic: First trimester: Increased risk of fetal alcohol spectrum disorders (FASD) in. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.